Výsledky vyhledávání - "Vaccines/adverse effects"

Akademický článek

Vaccination against COVID-19 and pregnancy

Autor: Nenad Veček, Tatjana Nemeth Blažić, Diana Nonković, Branka Arch-Veček, Slobodan Mihaljević

Publikováno v: Liječnički vjesnik, Vol 144, Iss 9-10, Pp 322-330 (2022)

Vaccine is the most effective preventive health measure that reduces the risk of developing a severe form of COVID-19 disease. Since it was determined that pregnant women were prone to develop more severe forms of the disease after being pregnant for

Externí odkaz: https://doaj.org/article/0cd3e7d69a204e9d9ecd6e014f75f725

Zobrazit plný text záznamu

Akademický článek

Coronavirus (COVID-19) vaccines

Autor: Mario Blekić, Blaženka Kljaić Bukvić

Publikováno v: Liječnički vjesnik, Vol 143, Iss 5-6, Pp 192-208 (2021)

A global pandemic of coronavirus disease requires a rapid solution by achieving the herd immunity with global vaccination. Production of the vaccines usually requires years of research and testing before they can be used. In 2020, the scientific comm

Externí odkaz: https://doaj.org/article/c8033b448e9f4731aeec45470974b414

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased

Autor: Diebold, Matthias, Locher, Eleonore, Boide, Philipp, Enzler-Tschudy, Annette, Faivre, Anna, Fischer, Ingeborg, Helmchen, Birgit, Hopfer, Helmut, Kim, Min Jeong, Moll, Solange, Nanchen, Giliane, Rotman, Samuel, Saganas, Charalampos, Seeger, Harald, Kistler, Andreas D

Publikováno v: Kidney international, vol. 102, no. 6, pp. 1409-1419

Numerous cases of glomerulonephritis manifesting shortly after SARS-CoV-2 vaccination have been reported, but causality remains unproven. Here, we studied the association between mRNA-based SARS-CoV-2 vaccination and new-onset glomerulonephritis usin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e4aecf781f9d083f107bd43fc22bbf7
https://doi.org/10.1016/j.kint.2022.08.021

Zobrazit plný text záznamu

Adverse events following first and second dose COVID-19 vaccination in England, October 2020 to September 2021:a national vaccine surveillance platform self-controlled case series study

Publikováno v: Tsang, R SM, Joy, M, Byford, R, Robertson, C, Anand, S N, Hinton, W, Mayor, N, Kar, D, Williams, J, Victor, W, Akbari, A, Bradley, D T, Murphy, S, O’Reilly, D, Owen, R K, Chuter, A, Beggs, J, Howsam, G, Sheikh, A, Hobbs, FD R & Lusignan, S D 2023, ' Adverse events following first and second dose COVID-19 vaccination in England, October 2020 to September 2021 : a national vaccine surveillance platform self-controlled case series study ', Eurosurveillance, vol. 28, no. 3 . https://doi.org/10.2807/1560-7917.ES.2023.28.3.2200195
Tsang, R SM, Joy, M, Byford, R, Robertson, C, Anand, S N, Hinton, W, Mayor, N, Kar, D, Williams, J, Victor, W, Akbari, A, Bradley, D T, Murphy, S, O'Reilly, D, Owen, R K, Chuter, A, Beggs, J, Howsam, G, Sheikh, A, Hobbs, FD R & de Lusignan, S 2023, ' Adverse events following first and second dose COVID-19 vaccination in England, October 2020 to September 2021 : a national vaccine surveillance platform self-controlled case series study ', Eurosurveillance, vol. 28, no. 3 . https://doi.org/10.2807/1560-7917.ES.2023.28.3.2200195
Tsang, R S, Joy, M, Byford, R, Robertson, C, Anand, S N, Hinton, W, Mayor, N, Kar, D, Williams, J, Victor, W, Akbari, A, Bradley, D T, Murphy, S, O'Reilly, D, Owen, R K, Chuter, A, Beggs, J, Howsam, G, Sheikh, A, Hobbs, FD R & de Lusignan, S 2023, ' Adverse events following first and second dose COVID-19 vaccination in England, October 2020 to September 2021: a national vaccine surveillance platform self-controlled case series study ', EUROSURVEILLANCE, vol. 28, no. 3, 2200195 . https://doi.org/10.2807/1560-7917.ES.2023.28.3.2200195

Background Post-authorisation vaccine safety surveillance is well established for reporting common adverse events of interest (AEIs) following influenza vaccines, but not for COVID-19 vaccines. Aim To estimate the incidence of AEIs presenting to prim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::605363ab9da8612afeb7c2fa34e6153e
https://research-information.bris.ac.uk/ws/files/367996381/eurosurv_28_3_4.pdf

Zobrazit plný text záznamu

Narcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy

Publikováno v: Nature Communications. 14(1)

Narcolepsy type 1 (NT1) is caused by a loss of hypocretin/orexin transmission. Risk factors include pandemic 2009 H1N1 influenza A infection and immunization with Pandemrix®. Here, we dissect disease mechanisms and interactions with environmental tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dris___00893::d4484df05a056c482bdabf471a3636e9
https://doi.org/10.1038/s41467-023-36120-z

Zobrazit plný text záznamu

Effectiveness and safety of coronavirus disease 2019 vaccines

Autor: Ting Shi, Chris Robertson, Aziz Sheikh

Publikováno v: Shi, T, Robertson, C & Sheikh, A 2023, ' Effectiveness and safety of coronavirus disease 2019 vaccines ', Current opinion in pulmonary medicine, vol. 29, no. 3, pp. 138-142 . https://doi.org/10.1097/MCP.0000000000000948

PURPOSE OF REVIEW: To review and summarise recent evidence on the effectiveness of coronavirus disease 2019 (COVID-19) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19 hospitalisation and death in a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcfba681d96c275c1ada7bde156e6c65
https://www.pure.ed.ac.uk/ws/files/329807621/Effectiveness_of_mRNA_boosters_after_homologous_primary_series_with_BNT162b2_or_ChAdOx1_against_symptomatic_infection_and_severe_COVID_19_in_Brazil_and_Scotland_A_test_negative_design_case_control_study_journal.pmed.1004156.pdf

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání